Traditionally, KRAS has been dubbed an “undruggable target,” evading the grasp of effective targeted therapies, thereby necessitating a focus on driver gene negative NSCLC for the long-term treatment of patients harboring KRAS mutations (7). This evidence concerns the gene KRAS and non-small cell lung carcinoma.